Researchers used a special microarray technology to identify immune responses in blood samples from people infected with Candida yeast. They found that early infections trigger antibodies against certain sugar structures, while later infections produce different antibodies. Three specific sugar molecules showed promise as markers for diagnostic tests and vaccine development against dangerous yeast infections.